52 articles with PhotoCure
Photocure ASA reported Hexvix®/Cysview® revenues of 53.5 million in the second quarter of 2020, corresponding to growth of three per cent, despite a significant Covid-19 impact in the beginning of the quarter in the U.S.
Photocure ASA, announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix® in Chile.
Reference is made to the OSE notification 27 April 2020 from Photocure ASA regarding the return of Hexvix® sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen Pharma SAS.
Photocure ASA (OSE: PHO), held its annual general meeting on 10 June 2020 at 17:00 hours (CET). All proposals were resolved as presented in the notice convening the annual general meeting dated 19 May 2020 , as further set out in the minutes from the general meeting attached hereto. For further information, please contact:
Photocure ASA announces the company's first sustainability report, which will be presented at the Annual General Meeting at 17:00 CET.
Photocure ASA announced key data was published by the 2020 American Urological Association Annual Virtual Meeting.
Photocure ASA announced the first quarter 2020 results in the trading update 27 April 2020, stating a revenue growth of 33% for the U.S.
Ipsen achieved Hexvix 2019 sales of EUR 18.7 million and Photocure sees significant growth opportunities in Europe
Photocure ASA, reported a revenue growth of 51% for the U.S. market in the fourth quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 58.8 million and a recurring EBITDA of NOK 1.6 million.
Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira®
Asieris MediTech Co, Ltd, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, and Photocure ASA, The Bladder Cancer Company, announced that they have entered into a License Agreement for world-wide development and commercialization of Cevira® for the treatment of HPV induced cervical precancerous lesions.
Expanded role for Cysview® (hexaminolevulinate HCl) in treating bladder cancer patients -- presented at the 2019 AUA Annual Meeting
Photocure ASA announced key data presented at the 2019 American Urological Association Annual Meeting in Chicago.
The approval of this new indication is based on the results from a large Phase 3 study.
Photocure ASA: Landmark Blue Light Cystoscopy With Cysview Study is Published in the Journal of Urology
Out of the 304 patients in the study, 103 were referred to the Operating Room for suspicion of recurrent bladder cancer.
Photocure ASA: Blue Light Flexible Cystoscopy With Cysview Phase III Study: New Data Presented at Society of Urological Oncology
Four separate posters were presented, including one using patient reported outcomes data from this study demonstrated the positive impact of Cysview on patient Quality of Life.
Photocure reported total group revenues of NOK 35.6 million in the third quarter of 2017 (35.2).
The U.S. Centers for Medicare & Medicaid Services has issued a Final Rule stating that it will reimburse hospital outpatient departments for certain Blue Light Cystoscopy (BLC(TM)) with Cysview procedures from January 1, 2018.
Photocure will present the report on Wednesday 8 November 2017 at Hotel Continental, Oslo, Norway.
With the FDA granting a priority review, a decision is expected in the first half of 2018.